MTOR and colorectal cancer: Overall, our results suggest that the PI3K/mTOR pathway inhibitor PF-04691502 has potent anti-proliferative activity in PIK3CA mutant CSCs, warranting further evaluation of the inhibitors in colorectal cancer patients carrying PIK3CA mutations.